Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is observing National Blood Cancer Awareness Month, joining patients, healthcare providers and patient organizations in raising public awareness of blood cancers and the need for continued research for novel treatment options. In support of patients and their loved ones, Infinity is launching the Sparks of Inspiration campaign. Throughout the month of September, Infinity encourages the submission of stories along with photos or illustrations to honor friends, family members and loved ones affected by blood cancer. For each submission received, Infinity will make a donation of $10 to the Leukemia & Lymphoma Society (LLS), the world's largest voluntary health organization dedicated to blood cancers. To learn more about Sparks of Inspiration and submit your tribute, please visit www.infi.com. “We are grateful for the support from Infinity, which highlights our shared goal of advancing new treatment options for patients affected by blood cancers,” said John Walter, president and CEO of LLS. “Blood Cancer Awareness Month is the right platform to create a sense of urgency about the need to continue investing in lifesaving treatments and cures. As there are no means of prevention of or early detection for most blood cancers, we must focus on cures.” “Infinity is committed to discovering and developing new medicines for patients with difficult-to-treat conditions, including blood cancers,” commented Pedro Santabarbara, M.D., Ph.D. chief medical officer at Infinity. “Through this campaign, we are honoring the courage and strength of patients with blood cancers and their families. We are pleased to support the Leukemia & Lymphoma Society’s mission of finding cures for blood cancers and improving the quality of life for patients and families.” Infinity is developing IPI-145, a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of certain blood cancers. “Early Phase 1 data of IPI-145 has shown encouraging signs of clinical activity across a broad range of blood cancers. I am excited to be involved in ongoing trials of IPI-145 and look forward to further evaluation of this investigational drug,” said Ian Flinn, M.D., Ph.D., director, hematologic malignancies program, Sarah Cannon Research Institute, and an investigator for these clinical studies of IPI-145. “New targeted agents in development, such as IPI-145, have the potential not only to expand therapeutic options for patients but also to reduce or delay the need for chemotherapy.”
The company is currently enrolling patients in a Phase 2 study (ClinicalTrials.gov Identifier NCT01882803) designed to evaluate the safety and efficacy of its lead product candidate, IPI-145, for the treatment of refractory indolent non-Hodgkin lymphoma (iNHL). Patients enrolled in this study must have progressed within six months of receiving their last therapy. Additionally, a Phase 1b investigator-sponsored trial of IPI-145 in patients with B-cell NHL, chronic lymphocytic leukemia (CLL) and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and bendamustine is also open for enrollment ( NCT01871675).More About Sparks of InspirationInfinity encourages the submission of stories along with photos and illustrations honoring friends, family members or loved ones affected by blood cancer. For each submission received, Infinity will make a $10 donation to the Leukemia & Lymphoma Society, up to a total of $5,000. Submissions can be made through Infinity’s website www.infi.com. Submissions will be accepted from September 3, 2013, through September 30, 2013. About the Development of IPI-145 for the Treatment of Blood CancersInfinity is developing IPI-145, a potent, oral inhibitor of Class I phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity. 1 The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies as well as inflammatory diseases. Infinity is currently enrolling patients with refractory indolent non-Hodgkin lymphoma (iNHL) in a Phase 2 study to evaluate the safety and efficacy of IPI-145 (ClinicalTrials.gov Identifier NCT01882803). An investigator-sponsored Phase 1b, open-label study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and bendamustine is also open for enrollment ( NCT01871675). Additionally, a Phase 1 study of IPI-145 in patients with advanced hematologic malignancies is ongoing ( NCT01476657). About Infinity Pharmaceuticals, Inc.Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at www.infi.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements regarding progress in clinical trials of the company’s PI3K program and the therapeutic potential of the company’s PI3K inhibitors. Important factors could cause actual results to differ materially from these forward-looking statements, including market conditions as well as risks and uncertainties associated with Infinity’s business, including those risks and uncertainties described in greater detail under the caption “Risk Factors” included in Infinity’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 8, 2013, and other filings filed by Infinity with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 1 Weinberg RA (2007) Cytoplasmic signaling circuitry programs many of the traits of cancer. In Jeffcock E, Zayatz E, and Mickey RK (Eds.) The biology of cancer (pp. 179-183). New York, NY: Garland Science, Taylor & Francis Group.